Stocks to Watch: Catalyst Pharmaceutical Partners, Mylan Inc, Avanir Pharmaceuticals, Actavis Inc

Lakeway, TX -- (SBWIRE) -- 03/11/2013 -- vbtrendreport.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

Catalyst Pharmaceutical Partners, Inc.(NASDAQ:CPRX) added 1.69% to $0.488. Catalyst Pharmaceutical Partners, Inc. is a development-stage biopharmaceutical company. The Company is focused on the development and commercialization of prescription drugs targeting addiction diseases and disorders of the central nervous system with a focus on the treatment of addiction and epilepsy. As of December 31, 2011, the Company had two drugs in development: CPP-109 and CPP-115. of December 31, 2011, it was evaluating its drug candidate, CPP-109 for the treatment of cocaine addiction.

How Should Investors Trade CPRX After The Solid Jump? Let’s Find Out Here

Mylan Inc.(NASDAQ:MYL) fell 1.30% and is trading at $30.33. Mylan, Inc. develops and markets generics along with a number of proprietary drugs. The Company's product is for the treatment of migraine headaches, an orphan drug for the on/off fluctuation in people with Parkinson's disease, and a wound care product to treat diabetic foot ulcers.

Is MYL Ready To Jump Again After The Solid Momentum? Get Free Trend Analysis Here

Avanir Pharmaceuticals, Inc.(NASDAQ:AVNR) is lower 0.81% to $3.07. AVANIR Pharmaceuticals, Inc. (AVANIR) is a pharmaceutical company focused on developing and commercializing therapeutic products for the treatment of central nervous system disorders. The Company focuses on products for the central nervous system. It also has a number of partnered programs in other therapeutic areas. Its docosanol 10% cream, sold in the United States and Canada as Abreva by its marketing partner GlaxoSmithKline Consumer Healthcare, is the only over-the-counter treatment for cold sores that has been approved by the United Sates Food and Drug Administration (FDA).

Is AVNR Buy After The Recent Price Movement? Find Out Here

Actavis Inc(NYSE:ACT) added 0.53% and is trading at $88.02. Actavis Inc., formerly Watson Pharmaceuticals, Inc., is an integrated global pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products. The Company operates in three segments: Global Generics, Global Brands and Distribution. It operates in international markets, including Western Europe, Canada, Australasia, Asia, South America and South Africa with its primary market being the United States.

Is ACT Buy After The Recent Price Movement? Find Out Here

About vbtrendreport.com
vbtrendreport.com’s team is engaged in providing stock newsletters on various hot penny stocks on a regular basis. Our instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. In order to get update to the markets, we would advise you sign up to our free newsletters. You can become leader in stock market by keeping track of the daily activity.

Disclaimer
The assembled information disseminated by vbtrendreport.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. vbtrendreport.com does expect that investors will buy and sell securities based on information assembled and presented in vbtrendreport.com. PLEASE always do your own due diligence, and consult your financial advisor.

?